SI3447061T1 - Farmacevtska formulacija, ki obsega fosforamidni derivat 5-fluoro-2'-deoksiuridina za uporabo pri zdravljenju raka - Google Patents

Farmacevtska formulacija, ki obsega fosforamidni derivat 5-fluoro-2'-deoksiuridina za uporabo pri zdravljenju raka

Info

Publication number
SI3447061T1
SI3447061T1 SI201231972T SI201231972T SI3447061T1 SI 3447061 T1 SI3447061 T1 SI 3447061T1 SI 201231972 T SI201231972 T SI 201231972T SI 201231972 T SI201231972 T SI 201231972T SI 3447061 T1 SI3447061 T1 SI 3447061T1
Authority
SI
Slovenia
Prior art keywords
deoxyuridine
fluoro
cancer
treatment
pharmaceutical formulation
Prior art date
Application number
SI201231972T
Other languages
English (en)
Inventor
Christopher Mcguigan
Jan Balzarini
Magdalena Slusarcyzk
Blanka Gonczy
Paola Murziani
Original Assignee
NuCana plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45841523&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI3447061(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1103582.1A external-priority patent/GB201103582D0/en
Priority claimed from GBGB1105660.3A external-priority patent/GB201105660D0/en
Application filed by NuCana plc filed Critical NuCana plc
Publication of SI3447061T1 publication Critical patent/SI3447061T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
    • C07F9/65842—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring
    • C07F9/65844—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring the phosphorus atom being part of a five-membered ring which may be condensed with another ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
SI201231972T 2011-03-01 2012-02-29 Farmacevtska formulacija, ki obsega fosforamidni derivat 5-fluoro-2'-deoksiuridina za uporabo pri zdravljenju raka SI3447061T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1103582.1A GB201103582D0 (sl) 2011-03-01 2011-03-01
GBGB1105660.3A GB201105660D0 (en) 2011-04-01 2011-04-01 Chemical compounds
EP18178715.1A EP3447061B1 (en) 2011-03-01 2012-02-29 Pharmaceutical formulation comprising a phosphoramidate derivative of 5-fluoro-2'-deoxyuridine for use in the treatment of cancer

Publications (1)

Publication Number Publication Date
SI3447061T1 true SI3447061T1 (sl) 2022-02-28

Family

ID=45841523

Family Applications (2)

Application Number Title Priority Date Filing Date
SI201231972T SI3447061T1 (sl) 2011-03-01 2012-02-29 Farmacevtska formulacija, ki obsega fosforamidni derivat 5-fluoro-2'-deoksiuridina za uporabo pri zdravljenju raka
SI201230488T SI2681227T1 (sl) 2011-03-01 2012-02-29 Fosforamidatni derivati 5-fluoro-2'-deoksiuridina za uporabo pri zdravljenju raka

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI201230488T SI2681227T1 (sl) 2011-03-01 2012-02-29 Fosforamidatni derivati 5-fluoro-2'-deoksiuridina za uporabo pri zdravljenju raka

Country Status (29)

Country Link
US (7) US8933053B2 (sl)
EP (4) EP2681227B1 (sl)
JP (1) JP5978232B2 (sl)
KR (1) KR101885940B1 (sl)
CN (2) CN103403013B (sl)
AU (1) AU2012223012C1 (sl)
BR (1) BR112013021986B1 (sl)
CA (1) CA2828326C (sl)
CL (1) CL2013002517A1 (sl)
CY (2) CY1117445T1 (sl)
DK (3) DK2681227T3 (sl)
ES (3) ES2686219T3 (sl)
HK (1) HK1192758A1 (sl)
HR (2) HRP20211967T1 (sl)
HU (2) HUE060127T2 (sl)
IL (1) IL228169A (sl)
LT (1) LT3447061T (sl)
MX (1) MX339822B (sl)
NZ (1) NZ615270A (sl)
PH (1) PH12015500485B1 (sl)
PL (3) PL3031812T3 (sl)
PT (2) PT3447061T (sl)
RS (2) RS54776B1 (sl)
RU (1) RU2614406C2 (sl)
SG (1) SG192841A1 (sl)
SI (2) SI3447061T1 (sl)
SM (1) SMT201600132B (sl)
WO (1) WO2012117246A1 (sl)
ZA (2) ZA201306468B (sl)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201016855D0 (en) 2010-10-06 2010-11-17 Nucana Biomed Ltd Chemical compounds
WO2012117246A1 (en) 2011-03-01 2012-09-07 Nucana Biomed Limited Phosphoramidate derivatives of 5 - fluoro - 2 ' - deoxyuridine for use in the treatment of cancer
SI3235824T1 (sl) 2012-11-16 2019-08-30 University College Cardiff Consultants Limited Zmes rp / sp gemcitabin-(fenil-(benziloksi-l-alaninil))-fosfata
WO2015013352A2 (en) * 2013-07-25 2015-01-29 Patel Hasmukh B Nucleoside phosphoramidates and phosphoramidites
CN104447923B (zh) * 2013-09-23 2018-03-30 中国药科大学 2’‑脱氧‑2’‑氟‑2’‑甲基核苷衍生物及其制备方法与在制药中的用途
RU2553996C1 (ru) * 2013-11-27 2015-06-20 Андрей Александрович Иващенко Замещенные (2r,3r,5r)-3-гидрокси-(5-пиримидин-1-ил)тетрагидрофуран-2-илметил арил фосфорамидаты
CN106659765B (zh) 2014-04-04 2021-08-13 德玛医药 二脱水半乳糖醇及其类似物或衍生物用于治疗非小细胞肺癌和卵巢癌的用途
WO2015181624A2 (en) * 2014-05-28 2015-12-03 Idenix Pharmaceuticals, Inc Nucleoside derivatives for the treatment of cancer
CN105153257B (zh) * 2014-06-12 2019-03-05 正大天晴药业集团股份有限公司 索非布韦的制备方法
RS60968B1 (sr) 2014-06-25 2020-11-30 NuCana plc Prolekovi gemcitabina
PL225283B1 (pl) * 2014-07-24 2017-03-31 Univ Im Adama Mickiewicza W Poznaniu Pochodne 2,3’-anhydro-2’-deoksy-5-fluorourydyny o działaniu cytotoksycznym, sposób wytwarzania i zastosowanie
DK3224268T3 (da) 2014-11-28 2019-09-02 NuCana plc Nye 2'- og/eller 5'-aminosyreesterphosphoramidat 3'-deoxyadenosinderivater som anti-cancerforbindelser
CN108368147A (zh) * 2015-05-27 2018-08-03 南方研究院 用于治疗癌症的核苷酸
CN108431016A (zh) * 2015-11-16 2018-08-21 艾可瑞恩治疗公司 核酸前体药物
GB201522764D0 (en) * 2015-12-23 2016-02-03 Nucana Biomed Ltd Formulations of phosphate derivatives
GB201609600D0 (en) * 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
GB201609601D0 (en) * 2016-06-01 2016-07-13 Nucana Biomed Ltd Phosphoramidate compounds
LU100724B1 (en) 2016-07-14 2018-07-31 Atea Pharmaceuticals Inc Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
EP3865136A1 (en) 2016-09-07 2021-08-18 ATEA Pharmaceuticals, Inc. 2'-substituted-n6-substituted purine nucleotides for corona virus treatment
EP3538124A4 (en) 2016-11-13 2020-07-22 Imagine Pharma COMPOSITIONS AND METHODS FOR TREATING DIABETES, HIGH BLOOD PRESSURE AND HYPERCHOLESTERINEMIA
CN109863160B (zh) 2016-12-23 2022-06-07 四川科伦博泰生物医药股份有限公司 核苷磷酸类化合物及其制备方法和用途
RU2644156C1 (ru) * 2017-02-28 2018-02-08 Александр Васильевич Иващенко Пролекарство ингибитора NS5B HCV полимеразы, способ его получения и применения
GB201709471D0 (en) * 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
JP2020530035A (ja) 2017-08-08 2020-10-15 スン・ヤット−セン・ユニバーシティＳｕｎ Ｙａｔ−Ｓｅｎ Ｕｎｉｖｅｒｓｉｔｙ 多剤耐性腫瘍を治療するための方法および組成物
GB201713916D0 (en) * 2017-08-30 2017-10-11 Nucana Biomed Ltd Treatment regimens
GB201715011D0 (en) 2017-09-18 2017-11-01 Nucana Biomed Ltd Floxuridine synthesis
GB201720279D0 (en) 2017-12-05 2018-01-17 Nucana Biomed Ltd Anticancer compounds
CN111836823B (zh) * 2018-03-09 2023-06-30 国立研究开发法人科学技术振兴机构 β修饰磷酸化合物前体、β修饰磷酸化合物、反应阻碍剂和包含这些化合物的医药品以及反应阻碍方法
CN110387226A (zh) * 2018-04-20 2019-10-29 天津大学 一种用于检测肿瘤的荧光探针及用途
US20220017940A1 (en) * 2018-11-30 2022-01-20 The University Of Tokyo Fluorescent probe for detecting carboxypeptidase activity
GB201904544D0 (en) 2019-04-01 2019-05-15 NuCana plc Anticancer compounds
CN110840907B (zh) * 2019-08-16 2022-11-25 南京医科大学 一类自由基敏感的尿嘧啶类ProTide前药及其药物用途
WO2021173713A1 (en) 2020-02-27 2021-09-02 Atea Pharmaceuticals, Inc. Highly active compounds against covid-19
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
EP4204428A1 (en) * 2020-08-31 2023-07-05 Emory University 5'-substituted nucleoside monophosphates, prodrugs thereof, and uses related thereto

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2802005A (en) 1957-08-06 S-eluorourace
US1002239A (en) 1902-04-11 1911-09-05 Stromberg Carlson Telephone Telephone system.
US2945038A (en) 1956-09-26 1960-07-12 Hoffmann La Roche 5-fluorocytosine and preparation thereof
US3201387A (en) 1963-09-18 1965-08-17 Heidelberger Charles 5-trifluoromethyluracil, derivatives thereof, and processes for preparing the same
US3792039A (en) 1971-12-27 1974-02-12 Miles Lab Poly 2'-fluoro-2'-deoxyuridylic acid
DD279248A1 (de) 1989-01-01 1990-05-30 Akad Wissenschaften Ddr Verfahren zur herstellung von 2',3'-didesoxythymidin-5'-diamidophosphaten
GB9505025D0 (en) * 1995-03-13 1995-05-03 Medical Res Council Chemical compounds
RU2197964C2 (ru) * 1995-04-12 2003-02-10 Дзе Проктер Энд Гэмбл Компани Фармацевтическая композиция, композиция стандартной лекарственной формы и способ лечения злокачественных новообразований, опухолей и вирусных инфекций
DK1045897T3 (da) * 1998-01-23 2002-05-13 Newbiotics Inc Enzymatisk katalyserede, terapeutiske midler
US7462605B2 (en) 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
JP4982019B2 (ja) 1999-07-22 2012-07-25 セルメド オンコロジー （ユーエスエイ）， インコーポレイテッド 酵素によって触媒される治療活性化
DE10109657A1 (de) 2001-02-28 2002-09-05 Menarini Ricerche Spa Verfahren zur Herstellung von (E)-5-(2-Bromvinyl)-2`-desoxyuridin
EP1404694A1 (en) 2001-06-21 2004-04-07 Glaxo Group Limited Nucleoside compounds in hcv
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
US8399428B2 (en) 2004-12-09 2013-03-19 Regents Of The University Of Minnesota Nucleosides with antiviral and anticancer activity
GB0505781D0 (en) 2005-03-21 2005-04-27 Univ Cardiff Chemical compounds
CA2618335C (en) 2005-08-15 2015-03-31 F.Hoffmann-La Roche Ag Antiviral phosphoramidates of 4'-substituted pronucleotides
US7888330B2 (en) 2005-11-09 2011-02-15 Wayne State University Phosphoramidate derivatives of FAU
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
CN101922935B (zh) 2010-07-16 2012-07-18 北京大学 一种最小互易结构干涉型全光纤陀螺仪
BR112013001267A2 (pt) 2010-07-19 2016-05-17 Gilead Sciences Inc métodos para a preparação de pró-fármacos de fosforamidato diasteromericamente puro
WO2012040126A1 (en) 2010-09-22 2012-03-29 Alios Biopharma, Inc. Substituted nucleotide analogs
CA2810928A1 (en) 2010-09-22 2012-03-29 Alios Biopharma, Inc. Substituted nucleotide analogs
WO2012048013A2 (en) 2010-10-06 2012-04-12 Inhibitex, Inc. Phosphorodiamidate derivatives of guanosine nucleoside compounds for treatment of viral injections
GB201016855D0 (en) 2010-10-06 2010-11-17 Nucana Biomed Ltd Chemical compounds
MY161407A (en) 2011-03-01 2017-04-14 Janssen Pharmaceutica Nv 6,7-DIHYDRO-PYRAZOLO[1,5-a]PYRAZIN-4-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE)
WO2012117246A1 (en) * 2011-03-01 2012-09-07 Nucana Biomed Limited Phosphoramidate derivatives of 5 - fluoro - 2 ' - deoxyuridine for use in the treatment of cancer
MX2020004054A (es) 2014-06-25 2021-11-30 NuCana plc Formulacion que comprende un profarmaco de gemcitabina.
DK3224268T3 (da) 2014-11-28 2019-09-02 NuCana plc Nye 2'- og/eller 5'-aminosyreesterphosphoramidat 3'-deoxyadenosinderivater som anti-cancerforbindelser
KR20180021697A (ko) 2015-05-14 2018-03-05 뉴카나 피엘씨 암 치료
GB201522764D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Formulations of phosphate derivatives
GB201609600D0 (en) 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives

Also Published As

Publication number Publication date
US11559542B2 (en) 2023-01-24
CN103403013B (zh) 2016-03-16
PT3447061T (pt) 2021-12-23
ZA201409013B (en) 2016-02-24
CN104974206A (zh) 2015-10-14
MX339822B (es) 2016-06-13
BR112013021986B1 (pt) 2021-07-27
PT3031812T (pt) 2018-10-18
CY1117445T1 (el) 2017-04-26
ZA201306468B (en) 2015-04-29
HUE029022T2 (en) 2017-02-28
CY1124871T1 (el) 2022-11-25
CN103403013A (zh) 2013-11-20
ES2569185T3 (es) 2016-05-09
ES2686219T3 (es) 2018-10-16
PL2681227T3 (pl) 2016-08-31
US20170312302A1 (en) 2017-11-02
JP5978232B2 (ja) 2016-08-24
US20220023330A1 (en) 2022-01-27
US11925658B2 (en) 2024-03-12
CA2828326A1 (en) 2012-09-07
MX2013009815A (es) 2014-03-21
ES2903097T3 (es) 2022-03-31
US9655915B2 (en) 2017-05-23
DK3447061T3 (da) 2022-01-03
US8933053B2 (en) 2015-01-13
IL228169A (en) 2016-07-31
EP2681227A1 (en) 2014-01-08
EP3447061A1 (en) 2019-02-27
SG192841A1 (en) 2013-09-30
US20160166596A1 (en) 2016-06-16
PL3031812T3 (pl) 2018-12-31
SI2681227T1 (sl) 2016-04-29
CN104974206B (zh) 2019-08-23
BR112013021986A2 (pt) 2016-11-16
US20150183817A1 (en) 2015-07-02
DK2681227T3 (da) 2016-02-22
EP3447061B1 (en) 2021-11-24
RU2614406C2 (ru) 2017-03-28
KR20140023913A (ko) 2014-02-27
US9221866B2 (en) 2015-12-29
EP3031812B1 (en) 2018-08-01
AU2012223012A1 (en) 2013-05-02
RU2013143862A (ru) 2015-04-10
HUE060127T2 (hu) 2023-02-28
EP3031812A1 (en) 2016-06-15
US20140057866A1 (en) 2014-02-27
EP4023299A1 (en) 2022-07-06
JP2014506913A (ja) 2014-03-20
US10022390B2 (en) 2018-07-17
HRP20211967T1 (hr) 2022-03-18
PL3447061T3 (pl) 2022-01-31
HRP20160346T1 (hr) 2016-05-06
WO2012117246A1 (en) 2012-09-07
US10993957B2 (en) 2021-05-04
AU2012223012B2 (en) 2015-06-18
HK1192758A1 (zh) 2014-08-29
CL2013002517A1 (es) 2014-07-25
PH12015500485A1 (en) 2017-04-10
AU2012223012C1 (en) 2015-09-03
CA2828326C (en) 2019-05-07
RS62721B1 (sr) 2022-01-31
DK3031812T3 (en) 2018-09-17
KR101885940B1 (ko) 2018-08-06
NZ615270A (en) 2015-09-25
PH12015500485B1 (en) 2017-04-10
RS54776B1 (sr) 2016-10-31
SMT201600132B (it) 2016-07-01
US20230165886A1 (en) 2023-06-01
LT3447061T (lt) 2022-01-25
US20190201432A1 (en) 2019-07-04
EP2681227B1 (en) 2016-02-10

Similar Documents

Publication Publication Date Title
HUE060127T2 (hu) Az 5-fluor-2'-deoxiuridin foszforamidát-származékot tartalmazó gyógyszerkészítmények a rák kezelésében való felhasználásra
SMT201400048B (it) Profarmaci carba-nucleosidici 1'-sostutuiti per iltrattamento antivirale
ZA201300692B (en) Administration of hypoxia activated prodrugs and antiagiogenic agents for the treatment of cancer
IL231536A (en) Indazole-3-carboxamides, pharmaceuticals containing them and their use in the treatment of diseases
EP2560624A4 (en) THERAPEUTIC FORMULATION TO REDUCE THE SIDE EFFECTS OF MEDICATION
GB201115711D0 (en) Phyto-cannabinoids for use in the treatment of cancer
GB2495841B (en) Phytocannabinoids for use in the treatment of breast cancer
IL221007A (en) Pharmaceutical combinations for antiviral therapy
ZA201409156B (en) Dna vaccine for use in pancreatic cancer patients
EP2740728A4 (en) URACIL DERIVATIVE AND ITS USE FOR MEDICAL PURPOSES
SI2780332T1 (sl) Morfolinilbenzotriazini za uporabo pri terapiji raka
GB2515440B (en) Vesicular Formulations for use in the treatment of Rosacea
ZA201301458B (en) Therapeutic agent for pain
EP2726869A4 (en) SOMATIC MUTATIONS OF ATRX IN BRAIN CANCER
HK1214771A1 (zh) 用於治療皮膚病的製劑
EP2905284A4 (en) PHOTOSENSITIZATION TARGETING THYMIDINE KINASE AND PHARMACEUTICAL COMPOSITION AND USE FOR THE TREATMENT OF ASSOCIATED CANCER
PL120295U1 (pl) Korpus pluga
AU2012900259A0 (en) Agents for use in cancer therapy
IL204097A0 (en) Medicine for the treatment of skin cancer